Andrew Mark Scott

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5581203/publications.pdf

Version: 2024-02-01

107 papers	6,964 citations	101543 36 h-index	60623 81 g-index
109 all docs	109 docs citations	109 times ranked	11712 citing authors

#	Article	IF	Citations
1	Antibody therapy of cancer. Nature Reviews Cancer, 2012, 12, 278-287.	28.4	1,861
2	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, The, 2021, 397, 797-804.	13.7	552
3	Bridging Bioâ€“Nano Science and Cancer Nanomedicine. ACS Nano, 2017, 11, 9594-9613.	14.6	304
4	The Impact of ⁶⁸Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Journal of Nuclear Medicine, 2018, 59, 82-88.	5.0	281
5	Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole. Seminars in Nuclear Medicine, 2007, 37, 451-461.	4.6	274
6	A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clinical Cancer Research, 2003, 9, 1639-47.	7.0	268
7	Antibodyâ€“Drug Conjugates for Cancer Therapy. Molecules, 2020, 25, 4764.	3.8	187
8	CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA. Journal of Urology, 2001, 166, 825-830.	0.4	186
9	Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncology, The, 2021, 22, e136-e172.	10.7	129
10	Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. Journal of Nuclear Medicine, 2006, 47, 410-8.	5.0	126
11	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nature Medicine, 2018, 24, 463-473.	30.7	120
12	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemotherapy and Pharmacology, 2017, 80, 1209-1217.	2.3	108
13	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. ELife, 2020, 9, .	6.0	104
14	Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. FEBS Journal, 2000, 267, 2505-2515.	0.2	101
15	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Current Opinion in Pharmacology, 2018, 41, 114-121.	3.5	97
16	Radiotheranostics in oncology: current challenges and emerging opportunities. Nature Reviews Clinical Oncology, 2022, 19, 534-550.	27.6	92
17	Antibodyâ€“drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nature Reviews Clinical Oncology, 2017, 14, 695-707.	27.6	90
18	First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. Journal of Clinical Neuroscience, 2015, 22, 1889-1894.	1.5	88

#	Article	IF	Citations
19	PET Changes Management and Improves Prognostic Stratification in Patients with Head and Neck Cancer: Results of a Multicenter Prospective Study. Journal of Nuclear Medicine, 2008, 49, 1593-1600.	5.0	85
20	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients withEGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro-Oncology, 2019, 21, 106-114.	1.2	84
21	PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study. Journal of Nuclear Medicine, 2008, 49, 1451-1457.	5.0	82
22	Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nature Neuroscience, 2016, 19, 798-806.	14.8	82
23	Evolution of anti-HER2 therapies for cancer treatment. Cancer Treatment Reviews, 2017, 59, 1-21.	7.7	73
24	Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment. Cancer Research, 2014, 74, 4470-4481.	0.9	71
25	Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Molecular Cancer Therapeutics, 2015, 14, 1141-1151.	4.1	70
26	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. Journal of Nuclear Medicine, 2020, 61, 626-629.	5.0	65
27	A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen. Clinical Cancer Research, 2007, 13, 3286-3292.	7.0	63
28	The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 428-448.	6.4	60
29	Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growthin vivo. International Journal of Cancer, 2001, 94, 645-651.	5.1	58
30	A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. PLoS ONE, 2015, 10, e0144559.	2.5	58
31	An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth. Journal of Experimental Medicine, 2016, 213, 1741-1757.	8.5	55
32	Long-Acting Somatostatin Analog Therapy Differentially Alters⁶⁸Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions. Journal of Nuclear Medicine, 2018, 59, 223-227.	5.0	48
33	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10009-10018.	7.1	46
34	18F-fluorodeoxyglucoseâ€“Positron Emission Tomography/Computed Tomography Aids Staging and Predicts Mortality in Patients With Muscle-invasive Bladder Cancer. Urology, 2014, 83, 393-399.	1.0	41
35	Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis. Lancet Oncology, The, 2020, 21, 1077-1088.	10.7	39
36	Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. British Journal of Clinical Pharmacology, 2001, 51, 177-180.	2.4	38

#	Article	IF	Citations
37	Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies. Molecular Immunology, 2015, 67, 75-88.	2.2	38
38	Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate. Molecular Cancer Therapeutics, 2018, 17, 795-805.	4.1	37
39	Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 347-353.	6.4	35
40	Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 1â€"Statement of the Issue and a Review of Available Resources. Journal of Nuclear Medicine, 2015, 56, 646-651.	5.0	32
41	Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth. EMBO Molecular Medicine, 2019, 11, .	6.9	32
42	Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics, 2019, 9, 1154-1169.	10.0	32
43	The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysis. Lancet Oncology, The, 2020, 21, 1089-1098.	10.7	32
44	Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis. Lancet Oncology, The, 2021, 22, 341-350.	10.7	32
45	Accuracy of Dose Calibrators for ⁶⁸Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment. Journal of Nuclear Medicine, 2018, 59, 636-638.	5.0	31
46	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibodyâ€"Drug Conjugate. Molecular Cancer Therapeutics, 2020, 19, 2117-2125.	4.1	30
47	Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector. Cancer Immunology, Immunotherapy, 2001, 50, 241-250.	4.2	27
48	Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 2â€"Current Standards and the Path Toward Global Standardization. Journal of Nuclear Medicine, 2016, 57, 1148-1157.	5.0	26
49	GPA33: A Marker to Identify Stable Human Regulatory T Cells. Journal of Immunology, 2020, 204, 3139-3148.	0.8	26
50	A simplified protocol for the automated production of succinimidyl 4â€{¹⁸F]fluorobenzoate on an IBA Synthera module. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 671-673.	1.0	22
51	Abnormalities at three musculoskeletal sites on whole-body positron emission tomography/computed tomography can diagnose polymyalgia rheumatica with high sensitivity and specificity. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2461-2468.	6.4	22
52	Detection of activated platelets in a mouse model of carotid artery thrombosis with 18F-labeled single-chain antibodies. Nuclear Medicine and Biology, 2014, 41, 229-237.	0.6	21
53	Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with ⁸⁹Zr-DS-8895a. Journal of Nuclear Medicine, 2016, 57, 974-980.	5.0	21
54	Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project. Journal of Nuclear Medicine, 2021, 62, 422-430.	5.0	20

#	Article	IF	Citations
55	Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. Rheumatology, 2018, 57, 345-353.	1.9	19
56	Mediators and clinical treatment for cancer cachexia: a systematic review. JCSM Rapid Communications, 2021, 4, 166-186.	1.6	19
57	Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.. Journal of Nuclear Medicine, 2021, 62, jnumed.120.254508.	5.0	19
58	Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. Experimental Hematology, 2017, 54, 31-39.	0.4	18
59	Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1476-1485.	6.4	15
60	Molecular Imaging Using PET/CT for Radiation Therapy Planning for Adult Cancers: Current Status and Expanding Applications. International Journal of Radiation Oncology Biology Physics, 2018, 102, 783-791.	0.8	14
61	The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis. Lancet Oncology, The, 2021, 22, 1301-1311.	10.7	14
62	Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget, 2015, 6, 38166-38180.	1.8	14
63	First clinical study of a pegylated diabody ¹²⁴I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. Theranostics, 2020, 10, 11404-11415.	10.0	13
64	Imaging of neuroinflammation in adult Niemann-Pick type C disease. Neurology, 2020, 94, e1716-e1725.	1.1	13
65	In Vitro and In Vivo Evaluation of ⁸⁹Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy. Theranostics, 2016, 6, 2225-2234.	10.0	12
66	Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-Î²RII fusion protein bintrafusp alfa. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3075-3088.	6.4	12
67	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. EBioMedicine, 2021, 65, 103252.	6.1	12
68	F-18 labelledN,N-bis-haloethylamino-phenylsulfoxides â€" a new class of compounds for the imaging of hypoxic tissue. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 1089-1103.	1.0	11
69	Antibody-drug conjugates: beyond current approvals and potential future strategies. Exploration of Targeted Anti-tumor Therapy, 0, , 252-277.	0.8	11
70	Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. EJNMMI Research, 2012, 2, 31.	2.5	10
71	Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1221-1227.	5.0	10
72	Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immunity, 2005, 5, 3.	3.2	10

#	Article	IF	Citations
73	Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system. Cancer Immunology, Immunotherapy, 2001, 50, 102-108.	4.2	9
74	Increasing Access to Imaging for Addressing the Global Cancer Epidemic. Radiology, 2021, 301, 543-546.	7.3	9
75	Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study. Blood, 2020, 136, 43-44.	1.4	9
76	Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. Lung Cancer, 2020, 150, 1-8.	2.0	8
77	11C labelling of AG957?a potential tyrphostin radiotracer for PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 157-165.	1.0	7
78	Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. Lung Cancer, 2021, 153, 35-41.	2.0	7
79	Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype. Blood, 2008, 112, 3900-3900.	1.4	7
80	Synthesis of 2â€[(4â€[¹⁸F]Fluorobenzoyloxy)methyl]â€1,4â€naphthalenedione from 2â€hydroxymethyl 1,4â€naphthoquinone and 4â€[¹⁸F]fluorobenzoic acid using dicyclohexyl carbodiimide. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 788-794.	1.0	6
81	Radiolabelling and evaluation of a novel sulfoxide as a PET imaging agent for tumor hypoxia. Nuclear Medicine and Biology, 2014, 41, 419-425.	0.6	6
82	Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics. Journal of Nuclear Medicine, 2021, 62, jnumed.120.254995.	5.0	6
83	In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET. Asia Oceania Journal of Nuclear Medicine and Biology, 2014, 2, 3-11.	0.1	6
84	Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CChum mice. PLoS ONE, 2018, 13, e0200649.	2.5	5
85	ATIM-23. PRELIMINARY FINDINGS OF A PHASE I SAFETY AND BIOIMAGING TRIAL OF KB004 (IFABOTUZUMAB) IN PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi6-vi6.	1.2	5
86	Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica. International Journal of Rheumatic Diseases, 2021, 24, 56-62.	1.9	5
87	The Australasian Radiopharmaceutical Trials Network: Clinical Trials, Evidence, and Opportunity. Journal of Nuclear Medicine, 2021, 62, 755-756.	5.0	4
88	Confocal Microscopy Reveals Cell Surface Receptor Aggregation Through Image Correlation Spectroscopy. Journal of Visualized Experiments, 2018, , .	0.3	3
89	ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414. Neuro-Oncology, 2018, 20, vi24-vi24.	1.2	2
90	Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. Nuclear Medicine and Biology, 2021, 93, 37-45.	0.6	2

#	Article	IF	Citations
91	AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2019, 134, 5332-5332.	1.4	2
92	Radiotherapy planning of lymphomas: role of metabolic imaging with PET/CT. Annals of Nuclear Medicine, 2022, 36, 162.	2.2	2
93	Is cholineâ€based PET imaging still relevant in recurrent prostate cancer?. BJU International, 2017, 120, 303-304.	2.5	1
94	GPA33 is expressed on multiple human blood cell types and distinguishes CD4⁺ central memory T cells with and without effector function. European Journal of Immunology, 2021, 51, 1377-1389.	2.9	1
95	11C-choline PET scanning is more accurate than biopsy in assessment of localized prostate cancer planned for radical prostatectomy.. Journal of Clinical Oncology, 2012, 30, 182-182.	1.6	1
96	Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. Blood, 2019, 134, 5328-5328.	1.4	1
97	Sensitization of Cancers Resistant to HER2 Antibodies. Critical Reviews in Oncogenesis, 2020, 25, 175-207.	0.4	1
98	CSIG-25. EPIDERMAL GROWTH FACTOR RECEPTOR EXTRACELLULAR DOMAIN MISSENSE MUTATION A289V AS A DRIVER OF GLIOBLASTOMA INVASION AND PROLIFERATION. Neuro-Oncology, 2018, 20, vi48-vi48.	1.2	0
99	Global Advancement of Nuclear Medicine: KSNM 60 Years of Achievements. Nuclear Medicine and Molecular Imaging, 2021, 55, 149-150.	1.0	0
100	Abstract CT101: Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma. , 2021, , .		0
101	Perspectives on Theranostics and Nuclear Medicine. Journal of Nuclear Medicine, 2021, 62, 1492-1494.	5.0	0
102	Automated synthesis of 18F radiolabelled indole containing Oncrasin-like molecules; a comparison of iodonium salts and boronic ester chemistry. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 23.	3.9	0
103	Automated processing of solid target 86Y using enriched SrO powder. Applied Radiation and Isotopes, 2022, 181, 110052.	1.5	0
104	2019 SNMMI Highlights Lecture: Oncology and Therapy. Journal of Nuclear Medicine, 2020, 61, 11N-17N.	5.0	0
105	2019 SNMMI Highlights Lecture: Oncology and Therapy, Part 2. Journal of Nuclear Medicine, 2020, 61, 7N-13N.	5.0	0
106	2020 SNMMI Highlights Lecture: Oncology and Therapy, Part 1. Journal of Nuclear Medicine, 2020, 61, 31N-40N.	5.0	0
107	2020 SNMMI Highlights Lecture: Oncology and Therapy, Part 2. Journal of Nuclear Medicine, 2021, 62, 14N-19N.	5.0	0